Biomarin Pharmaceutical Inc’s recent filing unveils that its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $92618.0 on Mar 19 ’25. In the deal valued at $71.52 per share,1,295 shares were sold. As a result of this transaction, Burkhart Erin now holds 16,955 shares worth roughly $1.21 million.
Then, Burkhart Erin bought 1,295 shares, generating $92,618 in total proceeds.
Before that, Guyer Charles Greg sold 7,034 shares. Biomarin Pharmaceutical Inc shares valued at $501,355 were divested by the EVP, Chief Technical Officer at a price of $71.28 per share. As a result of the transaction, Guyer Charles Greg now holds 87,655 shares, worth roughly $6.27 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock fall -0.64% to $71.53. Over the last five days, the stock has gained 0.01%. Biomarin Pharmaceutical Inc shares have risen nearly 8.82% since the year began. Nevertheless, the stocks have fallen -14.96% over the past one year. While a 52-week high of $94.85 was reached on 03/07/25, a 52-week low of $60.63 was recorded on 01/16/25. SMA at 50 days reached $66.92, while 200 days put it at $73.63.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 70.90, which if violated will result in even more drops to 70.26. On the upside, there is a resistance level at 72.21. A further resistance level may holdings at 72.89. The Relative Strength Index (RSI) on the 14-day chart is 59.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.90%. Stochastics %K at 62.21% indicates the stock is a holding.
How much short interest is there in Biomarin Pharmaceutical Inc?
A steep rise in short interest was recorded in Biomarin Pharmaceutical Inc stocks on 2025-03-14, growing by 0.3 million shares to a total of 4.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.47 million shares. There was a rise of 6.32%, which implies that there is a positive sentiment for the stock.
